Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05516121
Other study ID # KI-VLT-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 1, 2021
Est. completion date October 30, 2022

Study information

Verified date August 2022
Source Valentech LLC
Contact Max E Zapolski
Phone +79160890552
Email maxzapolski@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.


Description:

At stage 1, 15 stable patients diagnosed with schizophrenia take 1 tablet of VLT-015 (100 mg) followed by blood sampling to measure the level of the active substance and its main metabolite within 72 hours. After that patients have 3 days washout period. At the second stage, the same 15 patients take two 100 mg tablets of VLT-015 (200 mg) followed by blood sampling to measure the level of the active substance and its main metabolite within 72 hours. Then patients have the same 3 days washout period. At stage 3, the same patients take 2 tablets of VLT-015 (200 mg) consecutively for 2 days with 24-hours interval followed by blood sampling to measure the level of the active substance and its main metabolite within 96 hours. PK parameters are measured, tolerability and safety of the product are evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date October 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Male patients aged 18 to 50 - Availability of a voluntarily signed Information Consent (Patient Information Sheet) for participation in this clinical research and further hospitalization; - The diagnosis of schizophrenia established in the anamnesis - The patient's stay in remission** based on the decision of the investigator before and after the withdrawal of maintenance therapy. Criteria determining the state of remission: - the sum of points of the Positive and Negative Symptom Scale (PANSS) according to positive Marder factor is less than 22 points, - each item score of the positive Marder factor (delusions, hallucinatory behavior, grandiosity, suspicion, stereotyped thinking, somatic anxiety, unusual thought content, decreased criticism) less than 4 points - Absence of taking antipsychotic drugs for 5 periods half-life of the drug taken; - The patient's ability to adequately cooperate (the ability to understand provided information about the clinical trial, readiness for compliance with the requirements of the study protocol); - Agree to use barrier methods of contraception during the study and within 2 months after completion of the study. Exclusion Criteria: 1. The presence of contraindications to the use of VLT-015: - dysfunction of the bone marrow; - hypersensitivity to VLT-015 and other components of the drug; - toxic or idiosyncratic granulocytopenia/agranulocytosis in history; - epilepsy; - alcohol, drug intoxication and coma; - collapse, depression of the central nervous system of any etiology; - severe kidney or heart disease; - paralytic intestinal obstruction; - glucose-galactose malabsorption; - renal or hepatic insufficiency; 2. Patients requiring medication or other concomitant therapies listed in the unacceptable concomitant therapy section; 3. The presence of prostatic hyperplasia or glaucoma in patients; 4. Diseases of the bone marrow in history; 5. Active tuberculosis, cystic fibrosis, systemic connective tissue diseases, oncological processes of any localization; 6. Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen the prognosis patient, and also make it impossible to conduct a clinical trial); 7. Alcoholism and drug addiction at the present time, or in history; 8. Lack of patient willingness to cooperate, non-compliance of the patient; 9. Participation of the patient in any other clinical study in the last 30 days; 10. Patients planning to stay in the hospital during the study period for reasons other than the purposes of this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VLT-015
100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days

Locations

Country Name City State
Russian Federation Federal State Budgetary Scientific Institution "Mental Health Research Centre" Moscow Moscow Region
Russian Federation GBUZ SK Stavropol Regional Clinical Specialized Psychiatric Hospital No. 1 Stavropol' Stavropol Oblast

Sponsors (1)

Lead Sponsor Collaborator
Valentech LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Maximum plasma concentration 3 weeks
Primary Tmax Time to reach the maximum concentration 3 weeks
Primary AUC o-t Area under the pharmacokinetic curve, starting from time zero until the time of last blood sample collection 3 weeks
Primary AUC o - 8 Area under the pharmacokinetic curve, starting from time zero to infinity 3 weeks
Primary AUC o-t/AUC o-8 Share of AUC o-t of AUC o-8 expressed in % 3 weeks
Primary T1/2 Half-life, determined by the formula T_(1/2)= (ln?(2))/K_el 3 weeks
Primary MRT Mean retention time of the drug in the body, calculated from the start of the first time point to the time the last blood sample was taken 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A